Neuvivo is dedicated to creating therapeutics for the treatment of Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases. We have developed a patented macrophage-targeted technology, NP001, that addresses chronic inflammation, a key factor in the progressive loss of motor function in ALS.
NP001 has received Orphan Drug and Fast Track designation by the FDA as it addresses a clear unmet medical need. We are working to move this compound toward approval and delivering an effective and safe new treatment for ALS.
Company Details
- Employees
- 7
- Industry
- Biotechnology
- Website
- http://www.neuvivo.com
Neuvivo Questions
Neuvivo's website is http://www.neuvivo.com
Neuvivo's LinkedIn profile is https://www.linkedin.com/company/neuvivo
Neuvivo has
7 employees.
View email and phone details for 7
employees at Neuvivo.
Neuvivo's industry is
Biotechnology
Neuvivo's top competitors are
Jupiter Neurosciences, Inc.,
Tiziana Life Sciences,
Neurocrine Biosciences,
Oragenics, Inc,
Nrx Pharmaceuticals, Inc.,
Aiq Solutions,
Inhibikase Therapeutics, Inc.,
Grin Therapeutics, Inc.,
Mindmed,
Inbrain Pharma.
Neuvivo's categories are Biotechnology
